X9 wins FDA Breakthrough Device tag for dialysis cannulation system
X9, Inc. has secured FDA Breakthrough Device Designation for its X9 Ultrasound System with Power-Assisted Needle Insertion, a guidance and imaging platform designed to assist clinicians with needle placement during haemodialysis cannulation. The Connecticut-based medical technology company simultaneously announced the completion of ACCESS-2, its second clinical study of the investigational system.
The Breakthrough Device Designation was granted for the system's proposed use in identifying validated vascular access sites and guiding needle insertion into arteriovenous fistulae. The programme is intended to accelerate the FDA's review of devices addressing life-threatening or irreversibly debilitating conditions, though the designation does not constitute clearance or approval, and X9 has been explicit that the system is not yet available for commercial sale in the United States.
ACCESS-2 study findings
ACCESS-2 was a prospective, single-centre feasibility and safety study enrolling ten patients undergoing haemodialysis via arteriovenous fistula. Participants completed multiple dialysis sessions using device-assisted cannulation. The study demonstrated successful needle placement and subsequent initiation of dialysis across enrolled patients, and reported no serious device-related adverse events or other device-related adverse events, meeting its primary safety objective.
Eb Bright, chief executive of X9, described the dual announcement as "important progress in the development of technology with the potential to make vascular access more consistent and reproducible." He acknowledged that needle insertion into fistulae remains a technically demanding procedure for clinicians and a source of discomfort for patients undergoing treatment multiple times a week.
Kidney-care provider DaVita, which has invested in X9, also commented. Steve Phillips, DaVita's chief strategy officer, said the system "has the potential to change that, not just in kidney care, but across healthcare," pointing to broader applications for guided vascular access beyond haemodialysis.
Market context and competitive landscape
Vascular access reliability is a persistent clinical and commercial challenge in haemodialysis, where the roughly 550,000 patients receiving in-centre treatment in the United States typically attend three sessions per week. Repeated cannulation of arteriovenous fistulae carries risk of infiltration, haematoma and longer-term fistula damage, and variability in cannulation technique among nursing staff is a documented contributor to access failure.
Several established and early-stage companies are active in this space, including manufacturers of ultrasound-guided access devices used more broadly in vascular procedures. X9's approach of combining real-time imaging with power-assisted needle insertion is positioned by the company as purpose-built for the dialysis workflow, which operates under considerable time pressure in a high-throughput clinical setting.
X9 was incubated through ExploraMed, a California-based medical device incubator with a track record in cardiovascular and vascular technology. The DaVita investment adds a strategic clinical partner with direct access to dialysis units, which could prove material for eventual post-approval commercialisation and real-world data generation.
The company said it intends to advance through continued clinical development, and the Breakthrough Device pathway will give X9 access to more frequent FDA interactions and potentially priority review. Investors and clinicians will be watching for the design and scale of a pivotal study, the specific endpoints selected, and whether the system can demonstrate benefit in the more heterogeneous populations seen in a multicentre setting.